SUMMIT, N.J., April 3 /PRNewswire/ -- Novartis Consumer Health, Inc. and the National Basketball Association (NBA) announced today the signing of a multi-year agreement that includes media, marketing and promotional initiatives to support the Lamisil(AT) brand. Now an official sponsor of the NBA, Lamisil(AT) is a leading nonprescription athlete's foot medication and "the official athlete's foot remedy of the NBA." To complement this effort, a new Lamisil(AT) advertising campaign, set to launch later this spring, will feature NBA superstar Grant Hill. The partnership between NBA and Lamisil(AT) marks the first entry of a pharmaceutical product into the NBA promotional arena. "Lamisil(AT) has set a new standard for athlete's foot treatment, and is now doing the same for pharmaceutical marketing," noted MJ Weldon, category director for Dermatology at Novartis Consumer Health. "For us, Grant Hill was a natural choice because he personifies what Lamisil(AT) stands for -- 'strength, speed and endurance.' He is a leader both on and off the court." A gold-medal winning member of the 1996 USA Olympic Basketball Team, Grant Hill has accomplished a great deal in his professional life. He was rookie of the year during his first year in the NBA, and was the first rookie in NBA history to be the number one vote-getter for an All-Star Game. Every year since, Hill has been selected to the All-Star team, and has led the Detroit Pistons each season in points, rebounds, assists and steals. On the side, quietly but intently, Grant Hill devotes considerable money and time to making a positive difference in people's lives. The NBA-Lamisil(AT) agreement includes broadcast, print and online media advertising. Novartis Consumer Health also has the right to utilize the NBA logo and that of its member teams in Lamisil(AT) advertising. The Lamisil(AT) advertising campaign has been created by Grey Advertising, New York. "We're thrilled to enter into a new segment of integrated partnerships to extend the NBA's presence with a new type of company," stated Ken Derrett, senior vice president, Marketing Partnerships, NBA. "Lamisil(AT) is the quality sort partnership that we are excited about attracting to the roster of NBA partners." Lamisil(AT) Cream was launched in 1999 as the first nonprescription athlete's foot treatment requiring just one week of treatment for athlete's foot between the toes. Lamisil(AT) Spray Pump and Lamisil(AT) Solution Dropper were approved for nonprescription use on March 17, 2000 and will be available in supermarkets, drug stores and mass merchandise outlets this spring. Within weeks of its introduction, Lamisil(AT) became the number one over-the-counter athlete's foot cream. The NBA, headquartered in New York City, is comprised of 29 teams in the United States and Canada and is one of the world's largest providers of sports and entertainment programming. NBA.com is the NBA's official website with nearly six million impressions per day. Novartis Consumer Health, headquartered in Summit, New Jersey, manufactures, develops and markets a wide range of branded products the purpose of which is to restore, maintain or improve consumer health. Key businesses include OTC (over-the-counter medicines), Health and Functional Nutrition, Baby and Infant Business, Vitamins/Minerals/Supplements and Ingredients and Medical Nutrition products. For more information, contact Kate King of Novartis Consumer Health, 908-598-7039.
SOURCE Novartis Consumer Health, Inc.